CN115427551A - 人功能性角膜内皮细胞及其应用 - Google Patents

人功能性角膜内皮细胞及其应用 Download PDF

Info

Publication number
CN115427551A
CN115427551A CN202180030379.9A CN202180030379A CN115427551A CN 115427551 A CN115427551 A CN 115427551A CN 202180030379 A CN202180030379 A CN 202180030379A CN 115427551 A CN115427551 A CN 115427551A
Authority
CN
China
Prior art keywords
cells
cell
corneal endothelial
functional
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180030379.9A
Other languages
English (en)
Chinese (zh)
Inventor
木下茂
羽室淳尔
外园千惠
上野盛夫
户田宗豊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto Prefectural PUC
Original Assignee
Kyoto Prefectural PUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto Prefectural PUC filed Critical Kyoto Prefectural PUC
Publication of CN115427551A publication Critical patent/CN115427551A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
CN202180030379.9A 2020-02-27 2021-02-26 人功能性角膜内皮细胞及其应用 Pending CN115427551A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-032139 2020-02-27
JP2020032139 2020-02-27
PCT/JP2021/007490 WO2021172554A1 (ja) 2020-02-27 2021-02-26 ヒト機能性角膜内皮細胞およびその応用

Publications (1)

Publication Number Publication Date
CN115427551A true CN115427551A (zh) 2022-12-02

Family

ID=77491963

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180030379.9A Pending CN115427551A (zh) 2020-02-27 2021-02-26 人功能性角膜内皮细胞及其应用

Country Status (9)

Country Link
US (1) US20230257700A1 (https=)
EP (1) EP4116411A4 (https=)
JP (2) JP7807073B2 (https=)
KR (1) KR20220146552A (https=)
CN (1) CN115427551A (https=)
AU (1) AU2021225617A1 (https=)
BR (1) BR112022017180A2 (https=)
CA (1) CA3173725A1 (https=)
WO (1) WO2021172554A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021366805B2 (en) 2020-10-22 2025-04-24 Kyoto Prefectural Public University Corporation A storage method of human corneal endothelial cells and/or human corneal endothelial precursor cells
WO2024210619A1 (ko) * 2023-04-06 2024-10-10 재단법인 아산사회복지재단 줄기세포의 각막 내피 세포로의 직접 분화 유도용 조성물 및 이를 이용한 직접 분화 유도 방법

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678783B1 (en) 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
EP1195372A1 (en) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
JP3421217B2 (ja) 1995-11-20 2003-06-30 麒麟麦酒株式会社 Ｒｈｏ標的タンパク質Ｒｈｏキナーゼ
AU9646198A (en) 1997-10-22 1999-05-10 Nippon Shinyaku Co. Ltd. Isoquinoline derivative and drug
WO1999061403A1 (en) 1998-05-25 1999-12-02 Santen Pharmaceutical Co., Ltd. Novel vinylbenzene derivatives
UY27224A1 (es) 2001-03-23 2002-10-31 Bayer Corp Inhibidores de la rho-quinasa
PE20020958A1 (es) 2001-03-23 2002-11-14 Bayer Corp Inhibidores de la rho-quinasa
US7109208B2 (en) 2001-04-11 2006-09-19 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents
WO2002100833A1 (en) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
JP4505228B2 (ja) 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤
MXPA04007196A (es) 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
EP1541559A4 (en) 2002-07-22 2007-08-22 Asahi Kasei Pharma Corp 5-SUBSTITUTED ISOQUINOLINE DERIVATIVE
CA2400996A1 (en) 2002-09-03 2004-03-03 Lisa Mckerracher 1,4-substituted cyclohexane derivatives
US7160894B2 (en) 2003-06-06 2007-01-09 Asahi Kasei Pharma Corporation Tricyclic compound
WO2005003101A2 (en) 2003-07-02 2005-01-13 Biofocus Discovery Limited Pyrazine and pyridine derivatives as rho kinase inhibitors
WO2005039564A1 (en) 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Phthalimide compounds useful as protein kinase inhibitors
WO2005034866A2 (en) 2003-10-06 2005-04-21 Glaxo Group Limited Preparation of 1, 6, 7- trisubstituted azabenzimidazoles as kinase inhibitors
JP2007507547A (ja) 2003-10-06 2007-03-29 グラクソ　グループ　リミテッド キナーゼ阻害剤としての１，７−二置換アザベンゾイミダゾールの調製
ES2387780T3 (es) 2003-10-06 2012-10-01 Glaxosmithkline Llc Preparación de azabencimidazoles 1,6-disustituidos como inhibidores de quinasas
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
EP1679308B1 (en) 2003-10-15 2013-07-24 Ube Industries, Ltd. Novel indazole derivative
JP2007015928A (ja) 2003-10-15 2007-01-25 Ube Ind Ltd 新規オレフィン誘導体
CA2556589A1 (en) 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. 4-substituted piperidine derivatives
AR049333A1 (es) 2004-04-02 2006-07-19 Vertex Pharma Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas.
WO2006057270A1 (ja) 2004-11-26 2006-06-01 Asahi Kasei Pharma Corporation 含窒素３環化合物
CA2621181C (en) 2005-08-30 2011-04-19 Asahi Kasei Pharma Corporation 5-isoquinolinesulfonamide compounds
JP5761827B2 (ja) * 2011-07-15 2015-08-12 国立大学法人大阪大学 角膜内皮細胞の調製方法
EP2765188B1 (en) 2011-10-06 2017-12-06 Keio University Method for producing corneal endothelial cell
EP3029140A4 (en) * 2013-07-30 2017-06-28 Kyoto Prefectural Public University Corporation Corneal endothelial cell marker
WO2016129654A1 (ja) * 2015-02-12 2016-08-18 国立大学法人 東京大学 角膜内皮前駆細胞の調製方法
EP3416658B1 (en) * 2016-02-15 2023-03-22 Kyoto Prefectural Public University Corporation Human functional corneal endothelial cell and application thereof
JP2020032139A (ja) 2018-08-31 2020-03-05 株式会社三洋物産 遊技機

Also Published As

Publication number Publication date
BR112022017180A2 (pt) 2022-10-18
EP4116411A1 (en) 2023-01-11
AU2021225617A1 (en) 2022-10-13
JPWO2021172554A1 (https=) 2021-09-02
WO2021172554A1 (ja) 2021-09-02
KR20220146552A (ko) 2022-11-01
CA3173725A1 (en) 2021-09-02
EP4116411A4 (en) 2024-04-17
US20230257700A1 (en) 2023-08-17
JP2026027335A (ja) 2026-02-18
JP7807073B2 (ja) 2026-01-27

Similar Documents

Publication Publication Date Title
JP7453669B2 (ja) ヒト機能性角膜内皮細胞およびその応用
Rosario et al. Mechanistic target of rapamycin complex 1 promotes the expression of genes encoding electron transport chain proteins and stimulates oxidative phosphorylation in primary human trophoblast cells by regulating mitochondrial biogenesis
Kudryashova et al. Satellite cell senescence underlies myopathy in a mouse model of limb-girdle muscular dystrophy 2H
Anderson et al. Sterols lower energetic barriers of membrane bending and fission necessary for efficient clathrin-mediated endocytosis
JP2026027335A (ja) ヒト機能性角膜内皮細胞およびその応用
Xu et al. Impact of Brachyury on epithelial-mesenchymal transitions and chemosensitivity in non-small cell lung cancer
Wang et al. Cardiac fibroblast BAG3 regulates TGFBR2 signaling and fibrosis in dilated cardiomyopathy
Han et al. ANKRD1 aggravates renal ischaemia‒reperfusion injury via promoting TRIM25‐mediated ubiquitination of ACSL3
Xiong et al. Decidual stromal cell–derived exosomes deliver miR-22-5p_R-1 to suppress trophoblast metabolic switching from mitochondrial respiration to glycolysis by targeting PDK4 in unexplained recurrent spontaneous abortion
Zhang et al. Glucose metabolism disorder related to follicular fluid exosomal miR-122-5p in cumulus cells of endometriosis patients
Shi et al. Pseudouridine synthase 1 regulates erythropoiesis via transfer RNAs pseudouridylation and cytoplasmic translation
Li et al. Exosomes derived from mesenchymal stem cells increase the viability of damaged endometrial cells via the miR-99b-5p/PCSK9 axis
Su et al. Platelet-derived exosomal LINC00183 facilitate colorectal cancer malignant progression driven by histone lactylation through stabilizing ENO1
Ronan et al. Comprehensive multi-omics mapping of vesicle cargo from plasma or novel tissue vesicles reveals pathological changes in cargo with patient age
Wei et al. Kinesin-14 KIFC1 promotes acrosome formation and chromatin maturation during mouse spermiogenesis
Wang et al. UBE2S-mediated deubiquitination of GLUT1 via USP10 regulates glucose metabolic reprogramming and immune microenvironment to promote fibrosis in endometriosis
HK40078942A (en) Functional human corneal endothelial cells and application thereof
Huang et al. Does LIN28B gene dysregulation make women more likely to abort?
Meng et al. Shp2 regulates the trophoblast cell cycle progression through p53-p21 pathway modulation
Xiao et al. Oxidative phosphorylation pathway disruption is an alternative pathological mechanism leading to Diamond-Blackfan anemia
Gilglioni et al. Protein tyrosine phosphatase receptor kappa regulates glycolysis and de novo lipogenesis to promote hepatocyte metabolic reprogramming in obesity
Yang et al. Sestrins regulate age-induced deterioration of muscle stem cell homeostasis
Gao et al. USP5 stabilizes FoxM1 to enhance trophoblast proliferation, invasion and migration in recurrent spontaneous abortion
Jin et al. Embryo secretome regulation of the endometrial epithelial transcriptome: development of a model to test for embryo viability
Mahaffey et al. Axin promotes canonical Wnt signaling in the late primitive streak of mouse embryos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination